Martin Welschof, PhD, Chief Operating Officer & Managing Director of Affitech Research

Dr. Welschof is Chief Operating Officer and Managing Director of Affitech Research. He served Affitech AS as its CEO for 5 years. He co-founded Affitech AS while he was doing his post-doctoral training at the German Cancer Research Centre (DKFZ), Heidelberg, Germany.

After finishing his work at DKFZ where he established several important aspects of human antibody discovery systems, Dr. Welschof joined Axaron Bioscience AG, Heidelberg, Germany in 1999. As the Director of its technology division, Dr. Welschof oversaw the development of a large portfolio of cutting-edge technologies in the field of transcription analysis and functional genomics. Dr. Welschof also worked at Axaron’s parent company, LYNX Therapeutics Inc., Hayward, California, where he was instrumental in the development of LYNX’s parallel cloning and sequencing technologies MegaClone, MegaSort and MPSS.